Search
Gonyautoxin II
go.drugbank.com/drugs/DB19186InvestigationalGonyautoxin II is under investigation in clinical trial NCT04799041 (Gonyautoxin 2/3 in the Treatment of Acute Back Pain: A Clinical Proof-of-concept Study).
Padsevonil
go.drugbank.com/drugs/DB14977InvestigationalPadsevonil is under investigation in clinical trial NCT03695094 (A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on Padsevonil).
Brazikumab
go.drugbank.com/drugs/DB16115InvestigationalBrazikumab is under investigation in clinical trial NCT03759288 (An Active and Placebo-controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease).
Foralumab
go.drugbank.com/drugs/DB16170InvestigationalForalumab is under investigation in clinical trial NCT03291249 (Assessment of the Safety of Foralumab, an Oral Anti-cd3 Antibody, in Patients With NASH and T2DM).
Dihydroxyacetone phosphate
go.drugbank.com/drugs/DB04326InvestigationalDihydroxyacetone phosphate is an important intermediate in lipid biosynthesis and in glycolysis. Dihydroxyacetone phosphate has been investigated for the treatment of Lymphoma, Large-Cell, Diffuse.
Opnurasib
go.drugbank.com/drugs/DB21583InvestigationalOpnurasib is under investigation in clinical trial NCT05132075 (Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer … Opnurasib is a small molecule drug. The usage of the INN stem '-rasib' in the name indicates that Opnurasib is a Ras protein inhibitor.
Fenspiride
go.drugbank.com/drugs/DB08979InvestigationalFenspiride is an oxazolidinone spiro compound used as a drug in the treatment of certain respiratory diseases. … It is approved for use in Russia for the treatment of acute and chronic inflammatory diseases of ENT organs and the respiratory tract (like rhinopharyngitis, laryngitis, tracheobronchitis, otitis and sinusitis
Inetetamab
go.drugbank.com/drugs/DB17457InvestigationalInetetamab is a trastuzumab analog. It differs from trastuzumab by a two amino acid variation in its Fc domain (allotype variation), and possesses an exact F(ab’)2 of trastuzumab.
ONT-093
go.drugbank.com/drugs/DB14069ExperimentalIn pre-clinical studies, ONT-093 could inhibit P-gp and reverse multidrug resistance at nM concentrations with no effect on paclitaxel pharmacokinetics. … ONT-093 is an orally bioavailable inhibitor of P-glycoprotein (P-gp).